Puma Biotechnology traded at $2.66 this Tuesday July 5th, decreasing $0.12 or 4.32 percent since the previous trading session. Looking back, over the last four weeks, Puma Biotechnology lost 11.30 percent. Over the last 12 months, its price fell by 69.43 percent. Looking ahead, we forecast Puma Biotechnology to be priced at 2.70 by the end of this quarter and at 2.49 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,862.00 24.00 0.63% 4.80%
Daiichi Sankyo 3,475.00 16.00 0.46% 52.41%
Agios Pharmaceuticals 25.45 2.09 8.95% -55.55%
Alnylam Pharmaceuticals 150.73 2.48 1.67% -13.56%
Amgen 246.73 1.18 0.48% 1.26%
Biogen 212.58 1.95 0.93% -38.36%
Bluebird Bio 5.05 0.77 17.99% -83.73%
BioMarin Pharmaceutical 86.36 1.38 1.62% 2.12%
Clovis Oncology 2.41 -0.44 -15.44% -56.89%
Esperion Therapeutics 6.99 0.54 8.37% -64.80%
Exelixis 22.27 0.70 3.25% 21.10%
Gilead Sciences 62.34 -0.02 -0.03% -8.87%
Glaxosmithkline 43.30 -0.45 -1.03% 8.09%
Intercept Pharmaceuticals 15.15 1.02 7.22% -20.43%
Incyte Corp 79.25 1.58 2.03% -4.91%
MacroGenics 3.31 0.26 8.52% -88.38%
Moderna Inc 155.54 5.59 3.73% -33.34%
Mirati Therapeutics 71.96 0.78 1.10% -56.07%
Novartis 81.78 0.87 1.08% -3.28%
Puma Biotechnology 2.66 -0.12 -4.32% -69.43%
Pfizer 51.64 -0.67 -1.28% 31.43%
PTC Therapeutics 43.78 1.93 4.61% 0.99%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Regeneron Pharmaceuticals 596.56 1.16 0.19% 2.46%
Roche Holding 325.70 6.70 2.10% -7.86%
Seattle Genetics 176.77 -3.34 -1.85% 15.91%
Sangamo BioSciences 4.67 0.39 9.11% -58.49%
Spectrum Pharmaceuticals 0.80 0.03 3.68% -77.52%
Sarepta Therapeutics 75.74 0.03 0.04% 3.43%
TG Therapeutics 5.25 0.68 14.88% -86.49%
Vanda Pharmaceuticals 11.50 0.31 2.77% -43.41%
Vertex Pharmaceuticals 288.98 1.66 0.58% 45.22%

Indexes Price Day Year
US2000 1741 13.57 0.79% -23.44%

Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI), that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive metastatic breast cancer. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors. The Company has two subsidiaries: Puma Biotechnology Ltd and Puma Biotechnology, B.V.